OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the American College of Rheumatology Convergence 2022.
“ACR Convergence 2022 will have a great deal to offer practicing rheumatologists, scientists, educators, rheumatology professionals, and trainees,” said Annual Meeting Planning Committee Chair Sharon L. Kolasinski, MD, FACR, a professor of clinical medicine at the University of Pennsylvania, in a statement from the ACR.
ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.
ASAS40 responses increased between week 16 and week 52 in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.
Exposure to more than 100 mg was linked to significantly lower odds ratios for first-ever ACS event for women.